Crohn's Disease: Risankizumab for Children

We are studying the safety and effectiveness of risankizumab in children aged 2 to under 18 with moderately to severely active Crohn's disease. This trial aims to help those who haven't responded to other treatments.

>2 yearsConfirmation phase (III)Post-Trial Drug AccessPartially RemoteInvestigational MedicinesInjectionGastroenterologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Risankizumab
Risankizumab is a substance that blocks a specific immune signal to reduce skin inflammation in people with moderate to severe plaque psoriasis.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

AbbV-066

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
UZ Brussel
Pediatric Gastroenterology, Hepatology and Nutrition
Ganshoren, Belgium
UZ Leuven
Pediatrics
Heverlee, Belgium
Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola
Interventional Pediatrics
Jette, Belgium
Sponsor: Abbvie Deutschland GmbH & Co. KG
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.